We are live on ! Find out more
AQST icon

Aquestive Therapeutics
AQST

36 hedge funds and large institutions have $90.5M invested in Aquestive Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

6.88% less ownership

Funds ownership: 64.5% → 57.62% (-6.9%)

18% less funds holding

Funds holding: 44 → 36 (-8)

39% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 18

68% less capital invested

Capital invested by funds: $282M → $90.5M (-$191M)

Holders
36
Holders Change
-8
Holders Change %
-18.18%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
9
Reduced
9
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$2.16M
2
BlackRock
BlackRock
New York
+$2.15M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$1.52M
4
Squarepoint
Squarepoint
New York
+$377K
5
State Street
State Street
Massachusetts
+$351K

Top Sellers

1
CM
Crestline Management
Texas
-$201M
2
PA
Perceptive Advisors
New York
-$20.1M
3
PWAM
Park West Asset Management
California
-$6.9M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$2.11M
5
SFM
Sphera Funds Management
Israel
-$1.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$27K -$93.1K -7,375 -62%
AIG
27
American International Group
New York
$22K -$316 -25 -0.7%
MAM
28
Meeder Asset Management
Ohio
$20K +$41.6K +3,293 New
MWNA
29
Marshall Wace North America
New York
$14K +$27.5K +2,181 New
SO
30
STRS Ohio
Ohio
$9K – – –
JP Morgan Chase
31
JP Morgan Chase
New York
$8K +$1.58K +125 +10%
TRCT
32
Tower Research Capital (TRC)
New York
$7K +$14.9K +1,179 New
Citigroup
33
Citigroup
New York
$6K -$7.36K -583 -40%
Legal & General Group
34
Legal & General Group
United Kingdom
$5K – – –
AIP
35
Ameritas Investment Partners
Nebraska
$3K – – –
PCM
36
Prelude Capital Management
New York
$1K +$2.54K +201 New
CM
37
Crestline Management
Texas
– -$201M -11,503,294 Closed
PA
38
Perceptive Advisors
New York
– -$20.1M -1,150,000 Closed
PWAM
39
Park West Asset Management
California
– -$6.9M -394,000 Closed
SFM
40
Sphera Funds Management
Israel
– -$1.67M -95,300 Closed
Two Sigma Investments
41
Two Sigma Investments
New York
– -$773K -44,156 Closed
DIM
42
DC Investments Management
Virginia
– -$655K -37,384 Closed
BPIM
43
Brant Point Investment Management
New York
– -$622K -35,512 Closed
Citadel Advisors
44
Citadel Advisors
Florida
– -$451K -25,780 Closed
LCM
45
Landscape Capital Management
New Jersey
– -$357K -20,381 Closed
Point72 Asset Management
46
Point72 Asset Management
Connecticut
– -$350K -20,000 Closed
KeyBank National Association
47
KeyBank National Association
Ohio
– -$239K -13,644 Closed
BCM
48
BlueCrest Capital Management
Jersey
– -$238K -13,598 Closed
SSA
49
Schonfeld Strategic Advisors
New York
– -$196K -11,192 Closed
CSS
50
Cubist Systematic Strategies
Connecticut
– -$59K -3,387 Closed
1
2
3

AQST Hedge Fund Activity: Q4 2018 in Review

36 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2018, worth a combined $90.5M — down 68% from $282M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of AQST and 11 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 9 added.

The largest buyer was Massachusetts Financial Services, adding an estimated $2.16M. The largest seller was Crestline Management, exiting entirely with an estimated $201M sold.

  • 36 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2018, down from 44 in Q3 2018.
  • Funds reported $90.5M of Aquestive Therapeutics stock for Q4 2018, down 68% quarter-over-quarter.
  • 11 funds opened new Aquestive Therapeutics positions in Q4 2018 and 18 closed out, a net change of -7 holders.
  • The largest Aquestive Therapeutics buyer in Q4 2018 was Massachusetts Financial Services, an estimated $2.16M added.
  • The largest Aquestive Therapeutics seller in Q4 2018 was Crestline Management, an estimated $201M sold.

Based on aggregated 13F filings for Q4 2018.